Wedge Capital Management L L P NC Reduces Stock Holdings in United Therapeutics Corporation $UTHR

Wedge Capital Management L L P NC lessened its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 30.6% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 66,552 shares of the biotechnology company’s stock after selling 29,292 shares during the period. Wedge Capital Management L L P NC’s holdings in United Therapeutics were worth $27,899,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its position in United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after acquiring an additional 364,713 shares during the last quarter. Invesco Ltd. increased its stake in shares of United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares in the last quarter. Assetmark Inc. raised its position in shares of United Therapeutics by 38.1% during the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after purchasing an additional 197,384 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec raised its position in shares of United Therapeutics by 22.5% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company’s stock worth $147,278,000 after purchasing an additional 87,664 shares during the last quarter. Finally, Norges Bank purchased a new stake in United Therapeutics in the 2nd quarter valued at approximately $136,453,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. HC Wainwright increased their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Bank of America upped their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a research note on Monday, December 8th. Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Finally, UBS Group upped their target price on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Director Tommy G. Thompson sold 910 shares but still holds 8,480 shares (~$4.25M), signaling continued insider alignment with shareholders. SEC Filing — Thompson Sale
• Neutral Sentiment: All transactions were disclosed via SEC filings and covered by financial sites, providing transparency; investors should check the filings for whether sales were part of pre-set programs (e.g., 10b5-1) that reduce interpretive weight. SEC Filings
• Negative Sentiment: CEO Martine A. Rothblatt sold a total of 6,000 shares across Dec. 17 and Dec. 19 at ~ $501–$507, leaving her with only 130 shares — a ~94%+ reduction in reported ownership; that sharp drop can be read as a meaningful negative signal to some investors. SEC Filing — Rothblatt Sales
• Negative Sentiment: Additional senior insider sales: CFO and COO transactions reported (CFO ~$1.74M; COO ~$11.17M), increasing the volume and scope of executive selling within days — a likely near-term headwind for sentiment absent an explanatory disclosure. ABN: CEO Sale Coverage ABN: CFO Sale Coverage ABN: COO Sale Coverage

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $450.24, for a total value of $10,130,400.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders have sold 625,164 shares of company stock worth $284,916,107. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Stock Up 2.0%

Shares of NASDAQ:UTHR opened at $517.13 on Friday. The company has a market cap of $22.27 billion, a P/E ratio of 19.60, a P/E/G ratio of 5.13 and a beta of 0.86. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $518.61. The business has a fifty day simple moving average of $463.63 and a 200-day simple moving average of $380.95.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. During the same period in the prior year, the business posted $6.39 earnings per share. The firm’s revenue for the quarter was up 6.8% compared to the same quarter last year. Sell-side analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.